ANZCTR search results

The objective of this trial is to examine the effects of administration of kava (a plant medicine) on driving ability, cognition, mood and anxiety measures in comparison to oxazepam (a synthetic anti-anxiety drug) and placebo in adults aged 18-65 presenting with current mild to moderate levels of anxiety. Participants will be randomly allocated to one of three treatments at each session during the study (A,B,C). At the end of the study they will have taken all of the interventions individually. The treatments consist of kava, oxazepam, or placebo tablets consumed orally. A. Kava (180mg) – 3 X 60mg tablets taken in one session. B. Oxazepam (30mg tablet) - 1 tablet taken in one session. C. Oxazepam placebo 1 tablet taken in one session, or kava placebo 3tablets taken in one session

Cervical intraepithelial neoplasia 1, 2 or 3 is the term used to describe a range of cellular changes on the cervix that over time can regress to normal or progress to cervical cancer. Cervical cancers are usually preceded by a long phase of preinvasive disease. Evidence has shown that there is a 43% likelihood of regression of CIN 2, a 35% likelihood of persistence of CIN 2 and a 20% probability of progression to CIN 3. Evidence in adolescents has shown an even higher rate of regression. The current treatment for this abnormality is a LLETZ biopsy of the cervix. This treatment is associated with complications in future pregnancies – premature rupture of membranes and preterm labour. Because of the high regression rate and pregnancy complications, young women, up to age 25, with biopsy proven CIN 2 at Christchurch and Dunedin Hospitals will be offered inclusion in the study. This will involve 6 monthly colposcopy clinic visits where a cervical smear, biopsy and tests for HPV, Proex, P16, Ki67 as opposed to immediate surgical management. If there is progression of this change to CIN 3 throughout follow-up a LLETZ will be offered. Follow-up is for 24 months – if the CIN 2 abnormality persists, LLETZ will be offered.

The purpose of this study is to explore the individual and combined effects of common prescription medicines, at therapeutic doses, on driving performance. It is hypothesised that, while the interventions alone may not cause impairment, the combined effect of the medications will have an additive effect on driving performance.

The purpose of this study was to evaluate the novel soluble sublingual film dosage form of Suboxone(R) in comparison to the existing tablet dosage form. It was hypothesised that participants would prefer the novel dosage form to the existing tablet due to its ease of use and the added convenience it provided.

Given the limitations associated with previous studies of adverse events during chiropractic care, it is evident that controlled studies are warranted to develop a better understanding of the incidence of adverse events in chiropractic care. This proposition reflects the findings of a recent systematic review that concluded there were no robust data concerning the incidence or prevalence of adverse reactions after chiropractic and recommended urgent investigations to provide definite conclusions as to its safety profile. The principal aims of this study are to establish the frequency and severity of adverse effects from short term usual chiropractic treatment of the spine when compared to a sham treatment group. The secondary aim of this study is to establish the efficacy of usual short term chiropractic care for spinal pain when compared to a sham intervention. This will add to the literature on the efficacy of short term usual chiropractic care.

In a randomised design participants will be allocated to one of three conditions. Participants in the first condition will receive the standard CPT treatment. Those in the second condition will receive behavioural activation then CPT. And those in the third condition will receive CPT then behavioural activation. Given that research has not specifically examined the utility of using a combined treatment protocol for those with comorbid PTSD and MDD, the third condition will be added in an attempt to examine whether treatment presentation order makes a significant difference to treatment outcomes. Participants will be assessed at pre-treatment, mid-treatment, post-treatment and at a 6-month follow up. The project will use standardised self-report and structured clinical interview measures, and will use assessors blind to treatment condition at post- and follow-up assessments. It is predicted that: 1.Participants in all conditions will demonstrate a significant reduction in depression and PTSD symptoms. 2.Participants in the combined treatment conditions (behavioural activation then CPT or, CPT then behavioural activation) will show a greater reduction in PTSD and depression symptoms compared to participants in the CPT condition. 3. The relationship between depression symptoms and treatment outcomes (i.e., reduced PTSD and depression symptoms) will be mediated by emotional engagement.

Advanced prostate cancer is the second leading cause of cancer death in Australian men. Chemotherapy (Docetaxel) is effective in only 50% of patients with this disease. A molecule, MIC-1, is a potential predictive blood marker and mediator of Docetaxel resistance. This clinical trial will test whether the MIC-1 blood test is a predictor of Docetaxel resistance.

The study aims to determine if a group exercise and educational program provides benefit prior to hip or knee joint replacement surgery. Previous research has indicated that these programs can reduce pain and improve daily activities before surgery but it is not known whether these programs can improve confidence to manage the condition (self efficacy) prior to surgery. We will evaluate the effect of the program to be able to determine if it improves a patients confidence in managing their condition and it will also provide data that could be used to design a larger study in the future.

This study aims to assess the health benefits, harms, and costs of early detection for colorectal cancer in people with chronic kidney disease. Who is it for? You can join this study if you are aged 35-74 years and have chronic kidney disease in stages 3-5, have had a kidney transplant, or are on dialysis. You must be an Australian citizen or permanent resident who holds a Medicare and/or DVA gold card. You should have no personal or family history of colorectal cancer, no previous or current gastro-intestinal bleeding, no inflammatory bowel disease, and have not had a colonoscopy within the last two years. Trial details In this study, all participants will receive a home testing kit, called the immunochemical faecal occult blood test (IFOBT) kit. This will contain instructions, and additional explanation will be provided by study staff as required. The test will require participants to collect a sample from two of their separate bowel motions. The completed test kits will then be sent and processed in a laboratory to determine whether the result is negative, positive, or inconclusive. Participants with positive findings will be referred for a diagnostic colonoscopy. All diagnoses are recorded and communicated to participants. All participants will be followed up for a period of four years.